Vyvanse’s Long Shadow: Launch To Decide Fate Of Two Other Shire Drugs
Executive Summary
Shire is keeping two pending NDAs for new attention deficit hyperactivity disorder treatments in a sort of limbo while it waits to see if the high expectations for the launch of its d-amphetamine prodrug Vyvanse are fulfilled
You may also be interested in...
Shire Targets SHP465 ADHD Resubmission 10 Years After Initial Filing
Shire says it is on track to refile its long-shelved ADHD candidate SHP465 later this year after a Phase III trial in children and adolescents turned out positively.
Shire Expects Intuniv Launch In Mid-’09, As Firm’s ADHD Share Tops 30%
Shire plans to launch its nonstimulant ADHD candidate Intuniv in the second half of 2009, though new studies may be required to gain FDA approval
Shire Expects Intuniv Launch In Mid-’09, As Firm’s ADHD Share Tops 30%
Shire plans to launch its nonstimulant ADHD candidate Intuniv in the second half of 2009, though new studies may be required to gain FDA approval